Ocular Therapeutix
Update in progressOCUL (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Ocular Therapeutix, Inc. is a biopharmaceutical company applying bioresorbable hydrogel formulations to eye diseases in the United States. It markets DEXTENZA, a dexamethasone ophthalmic insert for post-surgical inflammation and pain, and allergic conjunctivitis. It is developing AXPAXLI (axitinib) in Phase 3 for wet AMD and NPDR, and OTX-TIC (travoprost) in Phase 2 for open-angle glaucoma/ocular hypertension. Licensed with AffaMed. Founded 2006, based in Bedford, MA.
Company score
- Sentiment
- 0.34
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.24
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.21
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!